9 studies found for:    1. RIVER PCI
Show Display Options
Rank Status Study
1 Completed Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
Conditions: Coronary Artery Disease;   Angina Pectoris
Interventions: Drug: Ranolazine;   Drug: Placebo
2 Terminated Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)
Conditions: Acute Coronary Syndrome;   Myocardial Infarction;   Coronary Artery Disease;   Percutaneous Coronary Intervention
Interventions: Drug: CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin;   Drug: Plavix (clopidogrel 75 mg) and aspirin
3 Recruiting Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Anemia;   Fever, Sweat, and Hot Flashes;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   Weight Change
Interventions: Drug: Ibrutinib;   Drug: Fludarabine Phosphate;   Drug: Cyclophosphamide;   Biological: Rituximab;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
4 Completed Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy
Condition: Acute Coronary Syndrome
Interventions: Drug: Otamixaban (XRP0673);   Drug: Otamixaban matching placebo;   Drug: Unfractionated Heparin;   Drug: Unfractionated Heparin matching placebo;   Drug: Eptifibatide;   Drug: Eptifibatide matching placebo
5 Recruiting Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: Ibrutinib;   Biological: Rituximab;   Drug: Bendamustine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
6 Completed Randomized Comparison Angioplasty Outcomes at Hospitals With and Without On-site Cardiac Surgery
Conditions: Coronary Arteriosclerosis;   Angina Pectoris
Intervention: Other: Percutaneous coronary intervention (PCI)
7 Unknown  Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
Conditions: Chemotherapeutic Agent Toxicity;   Fallopian Tube Cancer;   Neurotoxicity;   Ovarian Cancer;   Pain;   Peripheral Neuropathy;   Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin;   Drug: glutathione;   Drug: paclitaxel;   Other: placebo
8 Completed Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
Conditions: Chemotherapeutic Agent Toxicity;   Neuropathy;   Neurotoxicity Syndrome;   Pain;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Drug: Glutathione;   Other: Placebo;   Drug: Carboplatin;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
9 Recruiting Connect® MM- The Multiple Myeloma Disease Registry
Condition: Multiple Myeloma
Intervention:

Indicates status has not been verified in more than two years